Key Highlights

  • Diploma has quietly become one of the London market's most admired compounders.
  • The FTSE 100 group buys and builds specialist distribution and value-add businesses across controls, seals and life sciences, blending steady organic growth with a disciplined stream of acquisitions.
  • The first-half results, for the six months to 31 March 2026, were emphatic.
  • Revenue rose 17% to £851.1m, powered by organic growth of 15% — well ahead of the 9% delivered a year earlier — while adjusted operating profit jumped 33% to £208.9m and the Operating Margin expanded 300 basis points to...

Diploma has quietly become one of the London market's most admired compounders. The FTSE 100 group buys and builds specialist distribution and value-add businesses across controls, seals and life sciences, blending steady organic growth with a disciplined stream of acquisitions. Its 2026 financial year has been a showcase for that model, with repeated upgrades to guidance as both engines — organic and acquired growth — fire simultaneously. The recurring question for a serial acquirer trading at a premium is simply how long the run can last, and whether a rating built on years of double-digit compounding leaves any room for disappointment.

Repeated guidance upgrades

The first-half results, for the six months to 31 March 2026, were emphatic. Revenue rose 17% to £851.1m, powered by organic growth of 15% — well ahead of the 9% delivered a year earlier — while adjusted operating profit jumped 33% to £208.9m and the operating margin expanded 300 basis points to 24.5%. Adjusted Earnings Per Share climbed 36% to 109.2p. Management upgraded full-year organic growth guidance to 12%, and a subsequent third-quarter update, showing a further 15% organic advance, prompted another upgrade to the full-year outlook, underscoring the momentum running through the Business and the Operating Leverage that flows from higher volumes across a fixed distribution base.

How the buy-and-build machine works

Diploma's strategy is to acquire niche businesses that Supply essential components and consumables — items that are small parts of customers' costs but critical to their operations, giving pricing power and recurring Demand that is relatively insulated from the economic cycle. It then funds bolt-on deals from Cash Flow while nurturing organic growth. Over the Trailing Twelve Months the group completed 15 acquisitions for around £310m at an average multiple of about 8x, with seven deals since the first quarter alone costing roughly £180m. Crucially, deals are typically funded without recourse to equity, so growth accrues to existing shareholders rather than diluting them. Acquisitions are guided to add around 6 percentage points to reported growth this year, on top of the double-digit organic base.

A tale of three segments

Performance across the three divisions has been uneven. Controls, the largest and most acquisitive segment, surged 26% organically in the first half, driven by strength in aerospace, defence and industrial markets that are enjoying elevated order books. Seals grew a more modest 2%, and Life Sciences advanced 4%, reflecting softer conditions in parts of healthcare and North American industrials. The reliance on Controls means the group's headline momentum is closely tied to that division's end-markets, a concentration worth monitoring, though management has pointed to a healthy Acquisition pipeline that could rebalance the mix over time and broaden the sources of growth.

Balance sheet and returns

The financial model is cash-generative and conservatively funded. First-half free cash flow was £110.7m at 76% conversion, and leverage fell to a comfortable 0.8x net Debt to EBITDA, leaving ample capacity for further dealmaking without stretching the balance sheet. Return on adjusted trading Capital employed rose 360 basis points to 22.7%, a strong indicator of capital discipline, and the Interim Dividend was lifted 5% to 19.1p. The average acquisition multiple of 8-9x also compares favourably with Diploma's own market rating, making earnings-accretive deals easier to strike and creating value each time a lower-rated private business is folded into a higher-rated listed group. That combination of high returns, low leverage and self-funded M&A is the essence of the compounding story.

Outlook

The risks are those inherent to serial acquirers. Sustaining returns depends on continuing to source and integrate deals at sensible multiples; paying up in a competitive market, or misjudging an acquisition, would erode value. The heavy weighting to Controls and to industrial and aerospace end-markets exposes Diploma to cyclical downturns, while currency translation and a premium valuation add further sensitivity to any stumble. Potential catalysts include further guidance upgrades, sustained organic momentum, and continued bolt-on activity. Investors may watch whether the buy-and-build machine can keep converting acquisitions into the double-digit growth that has earned its lofty rating.